Literature DB >> 24596420

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.

Violaine Havelange1, Parvathi Ranganathan, Susan Geyer, Deedra Nicolet, Xiaomeng Huang, Xueyan Yu, Stefano Volinia, Steven M Kornblau, Michael Andreeff, Carlo M Croce, Guido Marcucci, Clara D Bloomfield, Ramiro Garzon.   

Abstract

Nucleophosmin-mutated acute myeloid leukemia (NPM1mut-AML) patients have a high rate of complete remission (CR) to induction chemotherapy. However, the mechanisms responsible for such effects are unknown. Because miR-10 family members are expressed at high levels in NPM1mut-AML, we evaluated whether these microRNAs could predict chemotherapy response in AML. We found that high baseline miR-10 family expression in 54 untreated cytogenetically heterogeneous AML patients was associated with achieving CR. However, when we included NPM1 mutation status in the multivariable model, there was a significant interaction effect between miR-10a-5p expression and NPM1 mutation status. Similar results were observed when using a second cohort of 183 cytogenetically normal older (age ≥ 60 years) AML patients. Loss- and gain-of-function experiments using miR-10a-5p in cell lines and primary blasts did not demonstrate any effect in apoptosis or cell proliferation at baseline or after chemotherapy. These data support a bystander role for the miR-10 family in NPM1mut-AML.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24596420      PMCID: PMC3983615          DOI: 10.1182/blood-2013-10-532374

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

2.  Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Authors:  Heiko Becker; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Peter Paschka; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

Review 3.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

4.  Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.

Authors:  Xiaomeng Huang; Sebastian Schwind; Bo Yu; Ramasamy Santhanam; Hongyan Wang; Pia Hoellerbauer; Alice Mims; Rebecca Klisovic; Alison R Walker; Kenneth K Chan; William Blum; Danilo Perrotti; John C Byrd; Clara D Bloomfield; Michael A Caligiuri; Robert J Lee; Ramiro Garzon; Natarajan Muthusamy; Ly James Lee; Guido Marcucci
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

Review 5.  Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.

Authors:  Brunangelo Falini; Paolo Sportoletti; Maria Paola Martelli
Journal:  Curr Opin Oncol       Date:  2009-11       Impact factor: 3.645

6.  MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

Authors:  Mojca Jongen-Lavrencic; Su Ming Sun; Menno K Dijkstra; Peter J M Valk; Bob Löwenberg
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

7.  MicroRNA 29b functions in acute myeloid leukemia.

Authors:  Ramiro Garzon; Catherine E A Heaphy; Violaine Havelange; Muller Fabbri; Stefano Volinia; Twee Tsao; Nicola Zanesi; Steven M Kornblau; Guido Marcucci; George A Calin; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

8.  miR-34a as part of the resistance network in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Julia Mohr; Eric Eldering; Arnon P Kater; Andreas Bühler; Dirk Kienle; Dirk Winkler; Jan Dürig; Marinus H J van Oers; Daniel Mertens; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

9.  Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.

Authors:  Ramiro Garzon; Michela Garofalo; Maria Paola Martelli; Roger Briesewitz; Lisheng Wang; Cecilia Fernandez-Cymering; Stefano Volinia; Chang-Gong Liu; Susanne Schnittger; Torsten Haferlach; Arcangelo Liso; Daniela Diverio; Marco Mancini; Giovanna Meloni; Robin Foa; Massimo F Martelli; Cristina Mecucci; Carlo M Croce; Brunangelo Falini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

10.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

View more
  28 in total

Review 1.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

Review 2.  The Globalization of Cooperative Groups.

Authors:  Manuel Valdivieso; Benjamin W Corn; Janet E Dancey; D Lawrence Wickerham; L Elise Horvath; Edith A Perez; Alison Urton; Walter M Cronin; Erica Field; Evonne Lackey; Charles D Blanke
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

3.  Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia.

Authors:  Yongjin Zhi; Xiaobao Xie; Rong Wang; Biao Wang; Weiying Gu; Yun Ling; Weimin Dong; Feng Zhi; Yan Liu
Journal:  Int J Hematol       Date:  2015-07-02       Impact factor: 2.490

Review 4.  Exploring clinical implications and role of non-coding RNAs in lung carcinogenesis.

Authors:  Swagata Roy; Neeldeep Ganguly; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.742

5.  CD4+ T cells from patients with acute myeloid leukemia inhibit the proliferation of bone marrow-derived mesenchymal stem cells by secretion of miR-10a.

Authors:  Zhen Yu; Dong Li; Xiu-li Ju
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-21       Impact factor: 4.553

Review 6.  MicroRNAome genome: a treasure for cancer diagnosis and therapy.

Authors:  Ioana Berindan-Neagoe; Paloma del C Monroig; Barbara Pasculli; George A Calin
Journal:  CA Cancer J Clin       Date:  2014-08-07       Impact factor: 508.702

7.  Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.

Authors:  Samaneh Sadat Seyyedi; Masoud Soleimani; Marjan Yaghmaie; Monireh Ajami; Mansoureh Ajami; Shahram Pourbeyranvand; Kamran Alimoghaddam; Seyed Mohammad Akrami
Journal:  Tumour Biol       Date:  2015-11-02

8.  miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.

Authors:  Arash Nanbakhsh; Géraldine Visentin; Daniel Olive; Bassam Janji; Eugenie Mussard; Philippe Dessen; Guillaume Meurice; Yanyan Zhang; Fawzia Louache; Jean-Henri Bourhis; Salem Chouaib
Journal:  Oncoimmunology       Date:  2015-10-16       Impact factor: 8.110

9.  miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.

Authors:  Timothy J Molloy; David D Ma; Thi Thanh Vu; Friedrich Stölzel; Kristy W Wang; Christoph Röllig; Melinda L Tursky
Journal:  Leukemia       Date:  2020-12-01       Impact factor: 11.528

10.  Role of Epithelial-Mesenchyme Transition in Chlamydia Pathogenesis.

Authors:  Joseph U Igietseme; Yusuf Omosun; Olga Stuchlik; Matthew S Reed; James Partin; Qing He; Kahaliah Joseph; Debra Ellerson; Brigid Bollweg; Zenas George; Francis O Eko; Claudiu Bandea; Hsi Liu; Genyan Yang; Wun-Ju Shieh; Jan Pohl; Kevin Karem; Carolyn M Black
Journal:  PLoS One       Date:  2015-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.